THERAVANCE BIOPHARMA, INC. (TBPH) Operating margin 2016–2025
THERAVANCE BIOPHARMA, INC. (TBPH) operating margin by fiscal year — reported operating income divided by reported revenue.
-3.4%FY2025 · since FY2016: -371.0% → -3.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -3.4% | +69.6 pp |
| FY2024 | -72.9% | +24.7 pp |
| FY2023 | -97.6% | +81.5 pp |
| FY2022 | -179.1% | +287.0 pp |
| FY2021 | -466.1% | -51.9 pp |
| FY2020 | -414.2% | -71.1 pp |
| FY2019 | -343.1% | +52.3 pp |
| FY2018 | -395.5% | +1295.2 pp |
| FY2017 | -1690.6% | -1319.7 pp |
| FY2016 | -371.0% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice